Trinity Biotech (TRIB) Cash from Investing Activities (2021 - 2024)

Trinity Biotech (TRIB) has reported Cash from Investing Activities for 4 consecutive years, with -$2.7 million the latest figure, recorded in Q4 2024.

• Quarterly Cash from Investing Activities fell 207.07% year-over-year to -$2.7 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$5.7 million (down 33.31% YoY) and the FY2025 annual result came in at -$6.2 million, up 72.91% from the prior year.
• Cash from Investing Activities eased to -$2.7 million in Q4 2024 per TRIB's latest filing, from -$891000.0 in the prior quarter.
• Over the last five years, Cash from Investing Activities for TRIB reached as high as -$1801.0 in Q2 2022 and fell as low as -$2.7 million in Q4 2024.
• A 4-year average of -$1.2 million and a median of -$1.0 million in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 54.02% — and 2024, when it slumped 207.07%.
• Year by year, Cash from Investing Activities stood at -$2.5 million in 2021, then soared by 54.02% to -$1.1 million in 2022, then increased by 21.7% to -$891000.0 in 2023, then sank by 207.07% to -$2.7 million in 2024.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$2.7 million, -$891000.0, and -$886000.0 for Q4 2024, Q4 2023, and Q3 2023 respectively.